875443-85-9

Upstream product

• 228107-82-2 [3,5-bis(trifluoromethyl)phenyl](hydroxy)acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 1502345-69-8 C₁₀H₅F₆NO 
• 401-95-6 3,5-Bis(trifluoromethyl)benzaldehyde 

Downstream Products

• 1584127-62-7 methyl 2-acetoxy-2-(3,5-di-trifluorpmethylphenyl)acetate 
• 1584127-74-1 C₁₁H₈F₆O₃ 
• 1584127-71-8 (S)-(+)-methyl 2-acetoxy-2-(3,5-di-trifluorpmethylphenyl)acetate 
• 875443-86-0 methyl [3,5-bis(trifluoromethyl)phenyl]({[5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)acetate 
• 151954-43-7 2-(3,5-bis(trifluoromethyl)phenyl)-2-bromoacetic acid methyl ester 

Relevant academic research and scientific papers

Ru-MACHO-Catalyzed Highly Chemoselective Hydrogenation of α-Keto Esters to 1,2-Diols or α-Hydroxy Esters

A ruthenium pincer catalyst has been shown to be highly effective for the hydrogenation of a wide range of α-keto esters, affording either diols or hydroxy esters depending on the choice of reaction conditions. Strong base, high temperature, and pressure favor the formation of diols whilst the opposite is true for the hydroxy esters.

Kinetic resolution of mandelate esters via stereoselective acylation catalyzed by lipase PS-30

By using lipase PS-30 as catalyst, the kinetic resolution of a series of racemic mandelate esters has been achieved via stereoselective acylation. The value of kinetic enantiomeric ratio (E) reached up to 197.5. Substituent effect is briefly discussed.

Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein

Recently, there has been a strong interest in the ability to increase levels of high density lipoprotein-cholesterol (HDL-C). This interest stems from the hypothesis that such an elevation in HDL-C will decrease the likelihood of cardiovascular disease. I

CETP INHIBITORS

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalky substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalky substituent connected directly to the ring or attached to the ring through a -CH2-.